Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer

Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue. This helps reduce side effects like urinary, sexual, and bowel problems. In a prospective observational expansion of a phase II clinical trial (ProAMFocal), 80% of patients with small, localized prostate cancers treated with FT had no cancer recurrence at one year, and 70% at 3 years after treatment. The investigators studied the genetic makeup of each cancer, and found that certain genetic markers and cancer

Trial Details

NCT ID

NCT07282808

Phase

NA

Sponsor

Singapore General Hospital

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Molecular Evaluation for Risk of Recurrence after FT

Locations (sample)

• Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

• Prostate Adenocarcinoma
• Grade Group 2-4
• MRI lesion size ≤3ml for single lesions ≤1.5ml for 2 lesions
• no gross EPE

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →